{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-027742","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2023-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.899766+00:00","generated_at":"2026-06-19T21:26:36.631067+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"RxSight prices public offering of 4M shares at $12.50 each for ~$50M gross proceeds","bullets":["Offering of 4,000,000 shares of common stock at $12.50 per share; gross proceeds ~$50.0M, net ~$46.7M.","Underwriters granted 30-day option to purchase up to 600,000 additional shares at same price.","Offering expected to close February 10, 2023; BofA Securities sole bookrunning manager.","Net proceeds to fund commercial expansion, product development, R&D, and working capital.","Officers and directors subject to 90-day lock-up restrictions on share sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-027742","json":"https://secwatch.observer/filing/0001193125-23-027742.json","markdown":"https://secwatch.observer/filing/0001193125-23-027742.md","text":"https://secwatch.observer/filing/0001193125-23-027742.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000119312523027742/0001193125-23-027742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000119312523027742/d426433d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T21:26:36.631067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"062ed414d94be4e4ac69a42d8e8e84d25ca9fd0f","claim":"RxSight, Inc. entered into Underwriting Agreement with BofA Securities, Inc., as representative of the several underwriters valued at approximately $46.7 million (effective 2023-02-07).","evidence_excerpt":"On February 7, 2023, RxSight, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative (the “Representative”) of the several underwriters listed in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell 4,000,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1111485/000119312523027742/0001193125-23-027742-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"BofA Securities, Inc., as representative of the several underwriters"},{"label":"Value","value":"approximately $46.7 million"},{"label":"Effective","value":"2023-02-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}